UniProt P61619
Protein transport protein Sec61 subunit alpha isoform 1 (P61619)
Protein transport protein Sec61 subunit alpha isoform 1 (UniProt P61619): 6 experimental structures on GenesisL1, 2 ligands bound, 32 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- P61619
- Protein
- Protein transport protein Sec61 subunit alpha isoform 1
- Experimental structures
- 6
- Predicted models
- 0
- Ligands
- 2
- Pockets
- 32 · 4 records with a druggable one
Structures
6 records of P61619 in the MolNFT archive: 6 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 8DNW | Cryo-EM structure of the human Sec61 complex in a partially-open apo state (Class 2) | electron microscopy | A | — | 7 (best 0.70) |
| 8DNY | Cryo-EM structure of the human Sec61 complex inhibited by decatransin | electron microscopy | A | — | — |
| 8DNZ | Cryo-EM structure of the human Sec61 complex inhibited by apratoxin F | electron microscopy | A | — | 10 (best 0.69) |
| 8DO1 | Cryo-EM structure of the human Sec61 complex inhibited by ipomoeassin F | electron microscopy | A | SXF | 9 (best 0.66) |
| 8DO3 | Cryo-EM structure of the human Sec61 complex inhibited by eeyarestatin I | electron microscopy | A | SWR | 6 (best 0.75) |
| P61619 | AlphaFold monomer V2.0 prediction for protein transport protein SEC61 subunit alpha isoform 1… | — | — | — |
Ligands
- SWR · N'-(4-chlorophenyl)-N-[(4R)-3-(4-chlorophenyl)-5,5-dimethyl-1-(2-{(2E)-2-[(2E)-3-(5-nitrofuran-2-yl)prop-2-en-1-ylidene]hydrazinyl}-2-oxoethyl)-2-oxoimidazolidin-4-yl]-N-hydroxyurea · in 1 record
- SXF · [(1~{S},3~{R},4~{S},5~{R},6~{R},8~{R},10~{S},23~{R},24~{R},25~{R},26~{R})-5-acetyloxy-6-methyl-4,26-bis(oxidanyl)-17,20-bis(oxidanylidene)-10-pentyl-24-[(~{E})-3-phenylprop-2-enoyl]oxy-2,7,9,21,27-pentaoxatricyclo[21.3.1.0^{3,8}]heptacosan-25-yl] (~{E})-2-methylbut-2-enoate · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.